In this Pharmaceutical Executive video interview, Edoardo Madussi, Head of Business Development, Intelligencia AI discusses ...

With continued investment and growing buzz from the industry, the AI hype is expected to extend through 2025 and beyond.

APAC offers stability in an increasing challenging global geopolitical environment for clinical stage drug development.

Peethaambaran Kunnathoor, Chennai Saturday, February 8, 2025, 08:00 Hrs [IST] ...

Bain Capital said its decision to buy Mitsubishi Tanabe is due to the “strong growth potential” of Japan’s healthcare ...

Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organization (CDMO) and bioanalytical ...

The pharmaceutical industry is on the verge of a significant transformation due to the emergence of artificial intelligence ...

DUBLIN--(BUSINESS WIRE)--The "Pharmaceutical ... the FDA's drug approval processes. Recently, the 21st Century Cures bill was passed, which is expected to speed up the approval process of the ...

3 CDMOs offer a wide range of comprehensive services to pharmaceutical companies, some of which can include supporting formulation development, upscaling current drug processes, clinical trial ...

“Enhancing productivity in pharmaceutical R&D is fundamental as it accelerates the development of new drugs, enabling companies to innovate ... Target identification follows as another crucial R&D ...